公开(公告)号：EP2216416B1

公开(公告)日：2012-05-09

申请号：EP10161334.7

申请日：1998-05-29

申请人： TrovaGene, Inc.

发明人： Lichtenstein, Anatoly V. ,  Melkonyan, Hovsep, S ,  Umansky, Samuil, R.

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6888 ,  C12Q1/6806 ,  C12Q1/6879 ,  C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/156 ,  Y10T436/143333 ,  C12Q2527/125 ,  C12Q2525/125

公开(公告)号：EP2357478A3

公开(公告)日：2011-11-16

申请号：EP10186268.8

申请日：2001-11-30

申请人： Crawford Healthcare Holdings Limited

发明人： Tazi-Ahnini, Rachid ,  Duff, Gordon ,  Cork, Michael ,  Ward, Simon ,  Bavik, Claes

IPC分类号： G01N33/68 ,  G01N33/564

CPC分类号： G01N33/564 ,  G01N33/6881 ,  G01N2500/00 ,  G01N2800/20 ,  G01N2800/205

摘要： We disclose a method of diagnosis of a disease, or susceptibility to a disease associated with abnormal cell-cell adhesion between epithelial cells, the method comprising detection of a mutation in a nucleic acid encoding an adhesion protein, a protease, or a protease inhibitor of an individual.

公开(公告)号：EP2338993A1

公开(公告)日：2011-06-29

申请号：EP10178401.5

申请日：2005-09-02

申请人： Yale University

发明人： Slack, Frank J. ,  Johnson, Steven M. ,  Grosshans, Helge

IPC分类号： C12N15/11 ,  A61K31/713 ,  A61K48/00 ,  A61P35/00

CPC分类号： C12N15/1135 ,  A61K31/7088 ,  A61K38/00 ,  A61K41/00 ,  A61K45/06 ,  A61K48/00 ,  C12N15/1136 ,  C12N15/1138 ,  C12N2310/111 ,  C12N2310/141 ,  A61K2300/00

摘要： Naturally occurring miRNAs that regulate human oncogenes and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. The compositions containing nucleic acids are administered to a patient in need of treatment or prophylaxis of at least one symptom or manifestation of cancer. In one embodiment, the compositions are administered in an effective amount to inhibit gene expression of one or more oncogenes. Methods for treatment or prevention of at least one symptom or manifestation of cancer are also described.

摘要翻译： 描述了调节人癌基因的天然存在的miRNA及其使用方法。 用于本文所述方法和组合物的合适核酸包括但不限于保留成熟miRNA和编码pri-miRNA的DNA的生物学活性的pri-miRNA，pre-miRNA，成熟miRNA或其变体的片段， miRNA，pre-miRNA，成熟miRNA，其片段或变体，或miRNA的调控元件。 将含有核酸的组合物给予需要治疗或预防癌症的至少一种症状或表现的患者。 在一个实施方案中，组合物以有效量施用以抑制一种或多种癌基因的基因表达。 还描述了用于治疗或预防至少一种癌症症状或表现的方法。

公开(公告)号：EP2315858A2

公开(公告)日：2011-05-04

申请号：EP09790154.0

申请日：2009-07-08

申请人： Source Precision Medicine, Inc.

发明人： BANKAITIS-DAVIS, Danute ,  SICONOLFI, Lisa ,  STORM, Kathleen ,  WASSMANN, Karl

IPC分类号： C12Q1/68 ,  G01N33/50

CPC分类号： G01N33/57434 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158

摘要： A method is provided in various embodiments for determining a profile data set for predicting the survivability of a subject with prostate cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification under measurement conditions that are substantially repeatable for measuring the amount of RNA corresponding to at least 1 constituent from Table 1. Alternatively, the method uses electrophoresis or immunohistochemistry for measuring the mount of protein corresponding to at least 1 constituent from Table 20. The profile data set comprises the measure of each constituent.

公开(公告)号：EP2301952A2

公开(公告)日：2011-03-30

申请号：EP10184924.8

申请日：2002-03-28

申请人： Synergy Pharmaceuticals, Inc.

发明人： Shailubhai, Kunwar ,  Nikiforovich, Gregory ,  Jacob, Gary S.

IPC分类号： C07K7/00 ,  C07K7/64 ,  A61K38/04 ,  A61K38/12 ,  A61P35/00 ,  A61P29/00

CPC分类号： C07K7/64 ,  A61K38/00 ,  A61K38/10 ,  A61K38/12 ,  A61K45/06 ,  A61K47/60 ,  C07K7/08 ,  C07K7/50 ,  C07K2299/00 ,  Y02A50/473

摘要： A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclise receptor and/or other small molecules that enhance intracellular production of cGMP. Then at least one peptide agonist of a guanylate cyclise receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia , inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.

摘要翻译： 公开了一种在哺乳动物受试者中治疗发炎，癌前或癌性组织或息肉的方法。 该治疗包括施用至少一种鸟苷酸环化受体的肽激动剂和/或增强细胞内cGMP产生的其它小分子的组合物。 那么至少一种鸟苷酸环化受体的肽激动剂可单独施用或与cGMP依赖性磷酸二酯酶抑制剂组合施用。 抑制剂可以是抑制cGMP降解的小分子，肽，蛋白质或其他化合物。 不需要特定的作用机制，这种治疗可以恢复受试者上皮细胞群体的增殖和凋亡之间的健康平衡，并且还抑制致癌作用。 因此，该方法可以用于治疗，特别是炎症，包括胃肠道炎症性疾病，一般器官炎症和哮喘，以及肺，胃肠道，膀胱，睾丸，前列腺和胰腺的致癌作用， 或息肉。

公开(公告)号：EP2300002A1

公开(公告)日：2011-03-30

申请号：EP09763480.2

申请日：2009-06-09

申请人： Vivus, Inc.

发明人： NAJARIAN, Thomas ,  TAM, Peter, Y. ,  WILSON, Leland, F.

IPC分类号： A61K31/35 ,  A61K31/137 ,  A61P3/04

CPC分类号： A61K31/357 ,  A61K9/1623 ,  A61K9/1629 ,  A61K9/167 ,  A61K9/1676 ,  A61K9/4866 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5084 ,  A61K31/00 ,  A61K31/135 ,  A61K31/137 ,  A61K31/35 ,  A61K31/7048 ,  A61K47/38 ,  A61K2300/00

摘要： The present invention is drawn to novel topiramate compositions as well as methods for treating obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention also features a pharmaceutical composition that includes, e.g., topiramate alone or in combination with a sympathomimetic agent and a novel escalating dosing strategy for administering such compositions.

公开(公告)号：EP2298878A2

公开(公告)日：2011-03-23

申请号：EP10185041.0

申请日：2001-11-02

申请人： Dana Farber Cancer Institute ,  OREGON HEALTH SCIENCES UNIVERSITY

发明人： D'Andrea, Alan D. ,  Taniguchi, Toshiyasu ,  Timmers, Cynthia ,  Grompe, Markus

IPC分类号： C12N15/00 ,  C07K14/00 ,  C07K16/00 ,  G01N33/574 ,  C12Q1/68 ,  A01K67/027

CPC分类号： G01N33/57484 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/47 ,  C07K16/18 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/5091 ,  G01N33/574 ,  G01N2500/00

摘要： Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, mapped on the 3p chromosome, cloned into recombinant vectors, used to prepare recombinant cells and sequenced. The FANCD2 gene sequence provides probes and primers for screening patients in genetic based test and for diagnosing Fanconi anemia and cancer. It has also been possible to target the FANCD2 gene in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. Vectors are described for use in gene therapy. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the mono-ubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact FA pathway. The FANCD2 has been localized to the nucleus and is associated with BRCA 1 foci.

摘要翻译： 提供了用于诊断癌症易感性，缺陷DNA修复机制及其治疗的方法和组合物。 在这里提供的序列中，已经鉴定了FANCD2基因，映射在3p染色体上，克隆到重组载体中，用于制备重组细胞并测序。 FANCD2基因序列提供探针和引物，用于筛选遗传基础测试患者和诊断范康尼贫血和癌症。 也可以在体内靶向FANCD2基因，以制备用于筛选用于治疗涉及有缺陷的DNA修复的病症的新治疗剂的实验小鼠模型。 描述了用于基因治疗的载体。 FANCD2多肽已被测序，已被证明存在于被鉴定为FANCD2-S和单泛素FANCD-L形式的两种同种型中。 已经制备了包括多克隆和单克隆抗体的抗体，其区分两种同种型并且已经用于诊断测试以确定受试者是否具有完整的FA途径。 FANCD2已被定位于细胞核，并与BRCA 1病灶相关。

公开(公告)号：EP2269070A1

公开(公告)日：2011-01-05

申请号：EP09720072.9

申请日：2009-03-16

申请人： DNAR, Inc

发明人： WEAVER, David, T. ,  WANG, XioaZhe ,  SPROTT, Kam, Marie

IPC分类号： G01N33/574 ,  C12Q1/68

CPC分类号： G01N33/57415 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56

摘要： The present invention provides methods of detecting triple negative breast cancer recurrence using biomarkers.

公开(公告)号：EP2264459A2

公开(公告)日：2010-12-22

申请号：EP10186256.3

申请日：2005-06-07

申请人： The Children's Hospital Medical Center ,  The Trustees of Columbia University

发明人： Devarajan, Prasad ,  Barasch, Jonathan M

IPC分类号： G01N33/53 ,  G01N33/536 ,  G01N33/537 ,  G01N33/543 ,  G01N33/551

CPC分类号： G01N33/6893 ,  G01N33/573 ,  G01N2333/82 ,  G01N2800/347 ,  G01N2800/52

摘要： A method and kit for detecting the early onset of renal disease and injury, including renal tubular injury, utilizing NGAL as an early blood serum biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

摘要翻译： 用于检测肾脏疾病和损伤早期发作的方法和试剂盒，包括肾小管损伤，利用NGAL作为早期血清生物标志物。 NGAL是小分泌的多肽，其是蛋白酶抗性的，因此在肾小管细胞损伤后血清中容易检测到。 主要在近端小管细胞中检测到NGAL蛋白质表达，以分泌蛋白质的点状胞质分布。 血清中的外观NGAL与肾缺血和肾毒血症的剂量和持续时间有关，是肾小管细胞损伤和肾衰竭的诊断。 NGAL检测也是监测药物或其他治疗剂的肾毒性副作用的有用标志物。

公开(公告)号：EP2258846A2

公开(公告)日：2010-12-08

申请号：EP10184602.0

申请日：1998-06-29

申请人： MEDICAL RESEARCH COUNCIL

发明人： Griffiths, Andrew ,  Tawfik, Dan

IPC分类号： C12N15/10 ,  C12Q1/68

CPC分类号： C12N15/1058 ,  C12N15/1062 ,  C12N15/1075 ,  C12Q1/6811 ,  C12Q2563/159

摘要： A method for increasing the concentration of a nucleic acid molecule, said method comprising:
(a) forming aqueous microcapsules from a water-in-oil emulsion, wherein a plurality of the microcapsules include a nucleic acid molecule and an aqueous solution comprising components necessary for nucleic acid amplification; and
(b) amplifying the nucleic acid molecule in the microcapsules to form further amplified copies of said nucleic acid molecule.

摘要翻译： 一种增加核酸分子浓度的方法，所述方法包括：（a）从油包水乳状液形成水性微胶囊，其中多个所述微胶囊包括核酸分子和水溶液，所述水溶液包含为 核酸扩增; 和（b）扩增微胶囊中的核酸分子以形成所述核酸分子的进一步扩增的拷贝。